Jacobs Levy Equity Management, Inc Arvinas, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 222,480 shares of ARVN stock, worth $2.35 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
222,480
Previous 176,242
26.24%
Holding current value
$2.35 Million
Previous $1.3 Million
46.11%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding ARVN
# of Institutions
237Shares Held
65.2MCall Options Held
1.23MPut Options Held
372K-
Vanguard Group Inc Valley Forge, PA8.56MShares$90.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$66.2 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA5.58MShares$58.9 Million5.5% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.35MShares$35.4 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.13MShares$22.5 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $562M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...